A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: Analysis of mutants producing reduced antibacterial activities

Typeset version

 

TY  - 
  - Other
  - Field, D,Collins, B,Cotter, PD,Hill, C,Ross, RP
  - 2007
  - July
  - A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: Analysis of mutants producing reduced antibacterial activities
  - Validated
  - 1
  - ()
  - random mutagenesis lacticin 3147 antimicrobial peptides lantibiotics peptide engineering SITE-DIRECTED MUTAGENESIS ANTIMICROBIAL PEPTIDE NISIN BROAD-SPECTRUM BACTERIOCIN AMINO-ACID SUBSTITUTIONS LACTOCOCCUS-LACTIS EXPRESSION SYSTEM LEADER PEPTIDE GENE-CLUSTER MUTACIN-II D-ALANINE
  - Lantibiotics are antimicrobial peptides that contain several unusual amino acids resulting from a series of enzyme-mediated posttranslational modifications. As a consequence of being gene-encoded, the implementation of peptide bioengineering systems has the potential to yield lantibiotic variants with enhanced chemical and physical properties. Here we describe a functional two-plasmid expression system which has been developed to allow random mutagenesis of the two-component lantibiotic, lacticin 3147. One of these plasmids contains a randomly mutated version of the two structural genes, ltnA1 and ltnA2, and the associated promoter, Pbac, while the other encodes the remainder of the proteins required for the biosynthesis of, and immunity to, lacticin 3147. To test this system, a bank of similar to 1,500 mutant strains was generated and screened to identify mutations that have a detrimental impact on the bioactivity of lacticin 3147. This strategy established/confirmed the importance of specific residues in the structural peptides and their associated leaders and revealed that a number of alterations which mapped to the -10 or -35 regions of Pbac abolished promoter activity. Copyright (c) 2007 S. Karger AG, Basel.
  - 226
  - 234
  - DOI 10.1159/000104747
DA  - 2007/07
ER  - 
@misc{V160959559,
   = {Other},
   = {Field,  D and Collins,  B and Cotter,  PD and Hill,  C and Ross,  RP },
   = {2007},
   = {July},
   = {A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: Analysis of mutants producing reduced antibacterial activities},
   = {Validated},
   = {1},
   = {()},
   = {random mutagenesis lacticin 3147 antimicrobial peptides lantibiotics peptide engineering SITE-DIRECTED MUTAGENESIS ANTIMICROBIAL PEPTIDE NISIN BROAD-SPECTRUM BACTERIOCIN AMINO-ACID SUBSTITUTIONS LACTOCOCCUS-LACTIS EXPRESSION SYSTEM LEADER PEPTIDE GENE-CLUSTER MUTACIN-II D-ALANINE},
   = {{Lantibiotics are antimicrobial peptides that contain several unusual amino acids resulting from a series of enzyme-mediated posttranslational modifications. As a consequence of being gene-encoded, the implementation of peptide bioengineering systems has the potential to yield lantibiotic variants with enhanced chemical and physical properties. Here we describe a functional two-plasmid expression system which has been developed to allow random mutagenesis of the two-component lantibiotic, lacticin 3147. One of these plasmids contains a randomly mutated version of the two structural genes, ltnA1 and ltnA2, and the associated promoter, Pbac, while the other encodes the remainder of the proteins required for the biosynthesis of, and immunity to, lacticin 3147. To test this system, a bank of similar to 1,500 mutant strains was generated and screened to identify mutations that have a detrimental impact on the bioactivity of lacticin 3147. This strategy established/confirmed the importance of specific residues in the structural peptides and their associated leaders and revealed that a number of alterations which mapped to the -10 or -35 regions of Pbac abolished promoter activity. Copyright (c) 2007 S. Karger AG, Basel.}},
  pages = {226--234},
   = {DOI 10.1159/000104747},
  source = {IRIS}
}
OTHER_PUB_TYPEOther
AUTHORSField, D,Collins, B,Cotter, PD,Hill, C,Ross, RP
YEAR2007
MONTHJuly
TITLEA system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: Analysis of mutants producing reduced antibacterial activities
RESEARCHER_ROLE
STATUSValidated
PEER_REVIEW1
TIMES_CITED()
SEARCH_KEYWORDrandom mutagenesis lacticin 3147 antimicrobial peptides lantibiotics peptide engineering SITE-DIRECTED MUTAGENESIS ANTIMICROBIAL PEPTIDE NISIN BROAD-SPECTRUM BACTERIOCIN AMINO-ACID SUBSTITUTIONS LACTOCOCCUS-LACTIS EXPRESSION SYSTEM LEADER PEPTIDE GENE-CLUSTER MUTACIN-II D-ALANINE
REFERENCE
ABSTRACTLantibiotics are antimicrobial peptides that contain several unusual amino acids resulting from a series of enzyme-mediated posttranslational modifications. As a consequence of being gene-encoded, the implementation of peptide bioengineering systems has the potential to yield lantibiotic variants with enhanced chemical and physical properties. Here we describe a functional two-plasmid expression system which has been developed to allow random mutagenesis of the two-component lantibiotic, lacticin 3147. One of these plasmids contains a randomly mutated version of the two structural genes, ltnA1 and ltnA2, and the associated promoter, Pbac, while the other encodes the remainder of the proteins required for the biosynthesis of, and immunity to, lacticin 3147. To test this system, a bank of similar to 1,500 mutant strains was generated and screened to identify mutations that have a detrimental impact on the bioactivity of lacticin 3147. This strategy established/confirmed the importance of specific residues in the structural peptides and their associated leaders and revealed that a number of alterations which mapped to the -10 or -35 regions of Pbac abolished promoter activity. Copyright (c) 2007 S. Karger AG, Basel.
PUBLISHER_LOCATION
PUBLISHER
EDITORS
ISBN_ISSN
EDITION
URL
START_PAGE226
END_PAGE234
DOI_LINKDOI 10.1159/000104747
FUNDING_BODY
GRANT_DETAILS